Which autoimmune disease can be linked with foot drop?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Autoimmune Diseases Linked with Foot Drop

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is the primary autoimmune disease associated with foot drop, and foot drop improves to anti-gravity power in most treated CIDP patients. 1

Primary Autoimmune Cause: CIDP

CIDP presents with progressive proximal and distal symmetric weakness, sensory loss, and depressed reflexes that develops over at least 8 weeks, distinguishing it from acute presentations. 2 The disease is driven by innate and adaptive immune pathways that target peripheral nerve components, though the exact etiopathogenesis remains incompletely understood. 2

Foot drop is common in CIDP, and recovery data shows that after initiation of standard immunomodulating treatment, ankle dorsiflexion power improved to anti-gravity strength (≥3/5) in 63% of patients (17/27) within one year. 1

Predictors of Recovery in CIDP-Related Foot Drop

The strongest predictors of foot drop recovery are: 1

  • Tibialis anterior compound muscle action potential amplitude at presentation (higher amplitude predicts better recovery)
  • Shorter disease duration before treatment initiation
  • Female gender

Pathophysiology

CIDP can damage peripheral nerves through two distinct mechanisms: 3

  • Macrophage-induced demyelination at internodal areas
  • Paranodal dissection (nodoparanodopathy) in cases with IgG4 antibodies against paranodal axoglial proteins, occurring without macrophage involvement

Approximately 30% of CIDP patients have immunoglobulin G that immunolabels nodes of Ranvier or paranodes of myelinated axons. 3

Secondary Autoimmune Cause: Guillain-Barré Syndrome (GBS)

While GBS is an acute autoimmune neuropathy (progressing over days to 4 weeks maximum), it can cause persistent foot drop requiring long-term management. 4, 5

GBS is triggered by preceding infections (Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae) and involves molecular mimicry where immune responses cross-react with peripheral nerves. 4

GBS Subtypes and Foot Drop Risk

  • Acute inflammatory demyelinating polyneuropathy (AIDP): Most common in Europe and North America, causes rapidly progressive symmetric weakness including foot drop 4
  • Acute motor axonal neuropathy (AMAN): More common in East Asia, targets gangliosides (GM1, GM1b, GD1a, GalNAc-GD1a) on motor axolemma causing axonal degeneration 4

Prognosis

GBS has approximately 10% mortality and 20% of patients are left with severe disability, which can include persistent foot drop requiring surgical intervention in refractory cases. 4, 5

Treatment Approach

For CIDP

Immunosuppressive and immunomodulating treatments are the cornerstone: 2

  • Intravenous immunoglobulin (IVIg) therapy
  • Plasma exchange
  • Corticosteroids (though less effective as monotherapy)

Treatment should be initiated promptly, as shorter disease duration before treatment predicts better recovery of foot drop. 1

For GBS

High-dose IVIg and plasma exchange aid rapid resolution through: 4

  • Complement inactivation
  • Neutralization of idiotypic antibodies
  • Cytokine inhibition
  • Saturation of Fc receptors on macrophages

Critical pitfall: Corticosteroids alone do not alter GBS outcome and should not be used as monotherapy. 4

Diagnostic Considerations

When evaluating foot drop for autoimmune etiology: 2, 3

  • Timeline is critical: Onset over <4 weeks suggests GBS; ≥8 weeks suggests CIDP
  • Electrodiagnostic testing: Assess tibialis anterior compound muscle action potential amplitude (prognostic for recovery) 1
  • Look for demyelinating features: Prolonged distal latencies, conduction velocity slowing, conduction block
  • Test for antibodies: IgG4 antibodies against paranodal proteins in suspected nodoparanodopathy 3

Autonomic symptoms (orthostatic dizziness, syncope) may accompany these neuropathies and should be assessed. 6, 7

References

2
Research

Acute/chronic inflammatory polyradiculoneuropathy.

Handbook of clinical neurology, 2023

5
Research

Bilateral Ankle and Subtalar Joint Fusion Secondary to Guillain Barré-Induced Foot Drop.

The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons, 2016

7
Guideline

Clinical Features and Management of Autonomic Neuropathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended treatment approach and dosage for pediatric patients diagnosed with Guillain-Barré Syndrome?
What is the differential diagnosis for a patient presenting with bilateral leg weakness, considering potential underlying conditions such as spinal cord compression, acute stroke, or Guillain-Barré syndrome?
Can a patient with Guillain-Barré Syndrome (GBS) affecting the lower extremities spontaneously develop weakness in the upper extremities?
Can Guillain-Barré Syndrome (GBS) present with tingling and weakness starting in the arms and then the mouth before progressing to the legs?
In a 56-year-old man who developed progressive lower and upper limb weakness a few weeks after a gastrointestinal infection, which of the following statements about acute inflammatory demyelinating polyneuropathy (Guillain‑Barré syndrome) is incorrect?
Does postural orthostatic tachycardia syndrome (POTS) cause long QT syndrome?
Does Caplyta (lumateperone) cause long QT syndrome?
What is the diagnosis and appropriate management for a solitary skin lesion on the left elbow?
What are loose bodies in a joint?
What is the Glasgow Coma Scale, how is it scored, and what do the scores indicate for patient management?
What does a low gamma‑glutamyl transferase (GGT) with an elevated alanine aminotransferase (ALT) indicate and what initial work‑up and management steps are recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.